TCF.LSE Theracryf Plc

Healthcare Biotechnology London Exchange
0.0017 GBX
Close of Nov 4, 2026
0.1600 0.2680
Market cap
GBX 3.65M
P/E
-
P/B
1.34x
ROE
-130.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Mar 2026.

Is TCF.LSE undervalued?

Graham number

The Graham number of Theracryf Plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Theracryf Plc fundamental analysis

No fundamental analysis for Theracryf Plc yet.

Theracryf Plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Theracryf Plc

Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of cancers, neurodevelopmental disorders, and other diseases. The company was formerly known as Evgen Pharma plc and changed it…

Full company profile